Status:
COMPLETED
A Survey Study to Assess the Accessibility of the Nerivio Device At School
Lead Sponsor:
Theranica
Conditions:
Migraine in Children
Eligibility:
All Genders
Up to 18 years
Brief Summary
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in t...
Detailed Description
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in t...
Eligibility Criteria
Inclusion
- Age ≤18 years old at registration to the Nerivio app
- Treated with Nerivio at least once (≥30 minutes/treatment).
- Attended elementary, middle, junior high, or high school, while first prescribed Nerivio
- Must obtain parent/legal guardian consent form prior to signing the assent form by the adolescent and engaging in study survey.
Exclusion
- None
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT06180577
Start Date
February 1 2024
End Date
May 15 2024
Last Update
November 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Theranica USA Inc
Bridgewater, New Jersey, United States, 08807